Slow intracellular accumulation of GABA(A) receptor delta subunit is modulated by brain-derived neurotrophic factor

S Joshi1, J Kapur

  • 1Department of Neurology, Box 800394, University of Virginia, Health Sciences Center, Charlottesville, VA 22908, USA.

Neuroscience
|August 12, 2009
PubMed

Insights

The delta subunit of GABA(A) receptors internalizes slower than the gamma2 subunit. Brain-derived neurotrophic factor (BDNF) enhances delta subunit surface expression.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Cell Biology

Background:

  • GABA(A) receptors, crucial for inhibitory neurotransmission, exhibit diverse subunit compositions.
  • The gamma2 and delta subunits of GABA(A) receptors have distinct cellular behaviors.
  • While gamma2 subunit trafficking is understood, delta subunit trafficking remains uncharacterized.

Purpose of the Study:

  • To investigate and compare the intracellular trafficking dynamics of the delta and gamma2 subunits of GABA(A) receptors.
  • To determine the factors modulating the surface expression of the delta subunit.

Main Methods:

  • Antibody feeding technique in cultured hippocampal neurons.
  • Biotinylation assay in organotypic hippocampal slice cultures.
  • Assessment of subunit internalization rates and surface half-life.

Main Results:

  • Delta subunit internalization peaked between 3-6 hours, significantly slower than the gamma2 subunit (30 min).
  • Surface half-life of the delta subunit was 102-171 minutes.
  • Brain-derived neurotrophic factor (BDNF) reduced delta subunit intracellular accumulation and increased surface expression, independent of network activity.

Conclusions:

  • The delta subunit exhibits distinct and slower intracellular trafficking kinetics compared to the gamma2 subunit.
  • BDNF signaling, via TrkB, PLCgamma, and PKC, positively modulates delta subunit surface stability.
  • Network activity influences delta subunit internalization, but BDNF's effect is independent of this activity.

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...